Xencor, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for XNCR, updated each market day.
XNCR AI Sentiment
AI sees no strong directional signal for Xencor, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Xencor, Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Sector
Exchange
Market Cap
$918,933,184
Cap Tier
Employees
260
Headquarters
PASADENA, CA
Listed Since
Dec. 3, 2013
Website
XNCR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
XNCR Volatility
Xencor, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
